Affiliation:
1. Institute of Economics of the Karelian Research Center RAS, Petrozavodsk, Russia
Abstract
The article studies the financial affordability of medicines for Russian families and its impact on the well-being of the population. Affordability of medicines depends on market conditions and government guarantees for free provision of medicines. Estimated drug consumption in the Russian Federation is based on microeconomic data from the nationwide Russia Longitudinal Monitoring Survey (RLMS-HSE) and pharmaceutical market data from DSM-Group. To assess the impact of pharmaceutical spending on poverty, disposable cash income per family member after deduction of medicines cost was calculated taking into account the poverty line. More than 2/3 of medicines in the Russian Federation are purchased by households on the commercial market. According to the study, every fifth household was at risk of poverty due to spending on medicines. The risk of poverty due to pharmaceutical costs is high in low-income families. Payments for medicines increase the number of families with out-of-pocket medical expenses by 5 times. Catastrophic spending on medicines in the Russian Federation reached its lowest level in 2021 according to the Universal Healthcare Coverage (UHC) criteria of the World Health Organization (WHO). There were no families that spent more than 100% of their income on medicines, and only 1.2% of families spent more than a quarter of their income. Every twentieth family refused to buy medicines at least once a year. In groups where the cost of medicines exceeded 10% of income, every tenth family refused to buy medicines. When the cost exceeded 25%, almost every fifth family refused to buy medicines. Thus, the rising prices and expenses for medicines are forcing Russian families to save on medicines and on their health. Recommendations for expanding the affordability of medicines for Russian families are given in the conclusion.
Publisher
Federal Center of Theoretical and Applied Sociology of the Russian Academy of Sciences (FCTAS RAS)
Subject
General Materials Science
Reference13 articles.
1. Kessides I., Miniaci R., Scarpa C., Valbonesi P. Toward Defining and Measuring the Affordability of Public Utility Services. World Bank policy research working paper. 2009. P. 3. DOI: 10.1596/1813–9450–4915
2. Meshkovsky A. P. O problemakh lekarstvennogo obespecheniya naseleniya [On the problems of public drug supply]. Meditsinskiye tekhnologii otsenka i vybor [Medical Technologies. Assessment and Choice]. 2015. No. 3. P. 21–33. (in Russ.)
3. Cameron A., Ewen M., Ross-Degnan D., Ball D., Laing, R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet. 2009. Vol. 373. No. 9659. P. 240–249.
4. Shashkova G. V. Mezhdunarodnyye nepatentovannyye naimenovaniya kak osnova formirovaniya ogranichitel’nykh perechney lekarstvennykh preparatov [International nonproprietary names as the basis for the formation of restrictive lists of medicines]. Vedomosti NTsESMP. [Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation]. 2012. No. 1. P. 38–41. (in Russ.)
5. Daikhes A. N., Fedyaev D. V. Obzor rossiyskikh i zarubezhnykh podkhodov k formirovaniyu gosudarstvennykh garantiy besplatnoy meditsinskoy pomoshchi [Provision of free medical care in Russia and elsewhere: review of regulatory and legal aspects]. FARMAKOEKONOMIKA [FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology]. 2017. Vol. 10. No. 3. P. 59–65. DOI: 10.17749/2070–4909.2017.10.3.059–065 (in Russ.)